pembrolizumab,n-803
merck,immunitybio
[]
additional data comparing n-803 vs pembro (kn-057) - karim chamie cr rate cis: 71% vs 41% cr rate cis, : 71% vs 29% cr rate cis/ht ta @ baseline: 81% vs 29% cr rate cis/t1 @ baseline: 67% vs 42% mdor of cr: 26.6 m vs 16.2 m rc rate: 15.8% vs 41.6% #asco22 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday